SARS-CoV-2 Recombinant Antigens

Serology testing is an important tool for monitoring the evolution of an outbreak. Serology tests that detect neutralizing antibodies are particularly useful for evaluating vaccine-induced protective immunity. As new SARS-CoV-2 variants emerge with mutations in the spike S protein, their potential to become “escape mutants” and negatively impact vaccine efficacy needs to be evaluated through neutralization testing.

Meridian’s new panel of SARS-CoV-2 mutant recombinant antigens represent the major circulating mutant strains and are suitable for use in neutralization studies and as controls in serology assays. They complement the existing range of high-performing SAR-CoV-2 wild-type antigens, several of which are in current EUA approved COVID-19 IgG/IgM serology tests.

All antigens are expressed in insect cells unless otherwise indicated.

Get In Touch With A Specialist

Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.

Learn More About Us

About Life Science
Welcome to
logo blue

Please select your country to continue